JGC
ITOS

J. Goldman & Co’s iTeos Therapeutics ITOS Stock Holding History

J. Goldman & Co’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,300
Closed -$209K – 521
2024
Q1 		$209K Buy
+15,300
New +$167K 0.01% 365

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

J. Goldman & Co's ITOS Position: Q4 2024 in Review

J. Goldman & Co sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 34,367 shares — an estimated $351K sold.

J. Goldman & Co first reported a position in ITOS in Q1 2021 and held it in 4 quarters. The position peaked at $1.44M in Q1 2021. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • J. Goldman & Co reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • J. Goldman & Co sold 34,367 iTeos Therapeutics shares in Q4 2024, an estimated $351K.
  • J. Goldman & Co first reported a position in iTeos Therapeutics in Q1 2021 and held it in 4 quarters.
  • J. Goldman & Co's iTeos Therapeutics position peaked at $1.44M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.